Mark White

Mark is a biopharmaceutical executive with global marketing, business development and sales experience at Pfizer, Abbott and Bayer.  Mark is currently CEO of NeuroKine Therapeutics, a faculty spin-out focused on development of selective kinase inhibitors for CNS diseases.  Mark is also an independent consultant and a member Robin Hood Ventures, a Philadelphia based angel investor group.  Mark held senior level roles at Pfizer in marketing and commercial development, where he led the successful global launches of Inspra, Revatio, Lyrica and Xeljanz.  In his last position, he was Vice President Worldwide Marketing, with global responsibility for new product development and in-line marketing for Pfizer’s Inflammation Therapeutic Area.  Prior to Pfizer, Mark worked for Bayer, Abbott, i-STAT and Bracco, in roles of increasing responsibility.  Mark has Bachelor and Master’s Degrees from the University of Missouri and received his MBA from the University of Chicago Booth School of Business.